Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Meningococcal disease
Pneumococcal disease
2023
Americas
Eastern Mediterranean
Clear all
Type of publications
NITAG documentation
(13)
Systematic reviews (SYSVAC)
(5)
Topics
Available to download in languages
Regions
Americas
(16)
Eastern Mediterranean
(2)
Africa
(8)
Europe
(19)
South-East Asia
(2)
Western Pacific
(5)
Countries
Argentina
(1)
Canada
(9)
Chile
(1)
Saudi Arabia
(2)
United States of America
(4)
Diseases
COVID-19
(12)
Meningococcal disease
(2)
Pneumococcal disease
(4)
Dengue
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Human papillomavirus (HPV)
(2)
Influenza
(2)
Poliomyelitis
(1)
RSV (Respiratory syncytial virus)
(5)
Vaccine topics
Acceptance
(2)
Coverage
(1)
Efficacy/effectiveness
(1)
Ethical issues
(1)
Safety
(2)
Target population
Adolescents
(1)
Adults
(3)
All age groups
(3)
Newborn
(1)
Older adults
(2)
Publication date
2023
(18)
2024
(3)
2022
(47)
2021
(65)
2020
(65)
2019
(8)
2018
(9)
2017
(2)
2016
(10)
2015
(6)
2014
(8)
2013
(6)
2012
(2)
2011
(3)
2010
(5)
2009
(1)
2008
(3)
2007
(2)
2006
(3)
2005
(1)
2004
(2)
2003
(3)
2002
(2)
1997
(2)
18 results found
2023
∙
ACIP
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
2023
∙
NACI
Guidance on the use of COVID-19 vaccines in the fall of 2023
2023
∙
NACI
NACI Interim guidance on the use of bivalent Omicroncontaining COVID-19 vaccines for primary series
2023
∙
NACI
Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
2023
∙
NACI
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
2023
∙
NACI
Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
2023
∙
NACI
Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
2023
∙
NACI
NACI guidance on COVID-19 vaccine booster doses: Initial considerations for 2023
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register